

**Exhibit 1.**

**Doxycycline EUA Fact Sheet for Health Care Professionals**

# Doxycycline EUA Fact Sheet for Health Care Professionals

**Dear Health Care Professional:** If you have received this Fact Sheet, an event has occurred that calls for the emergency use of doxycycline. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the distribution of doxycycline to people who may have been exposed to *Bacillus anthracis* (*B. anthracis*), the causative pathogen of anthrax. Doxycycline is FDA-approved to reduce the incidence or progression of disease following exposure to aerosolized *B. anthracis*, including post-exposure prophylaxis (PEP) of inhalational anthrax. However, certain uses provided for under this EUA are not FDA-approved and would not be consistent with relevant statutes and regulations under normal circumstances, e.g., distribution without a prescription.<sup>1</sup> For more information on this EUA, see FDA's web page at [www.fda.gov](http://www.fda.gov).

## What are the symptoms of anthrax?

First symptoms are cold-like or flu-like symptoms, e.g., sore throat, mild fever, myalgias. Later symptoms are cough, chest discomfort, shortness of breath, fatigue, and myalgias. Symptoms usually occur within 7 days of inhaling anthrax germs, but can take up to 42 days to appear.

## Who cannot take doxycycline?

Anyone allergic to doxycycline, or another tetracycline, must ***not*** be given doxycycline.

## What is the usual dose of doxycycline?

- The full PEP regimen is usually 60 days. Patients may not have received a full PEP regimen in response to this anthrax incident; public officials will announce where and when they can get the rest of the medicine.
- Adults (≥18) who can swallow tablets or children who weigh 40 kg (89 lbs) or more and can swallow tablets should receive one tablet (100 mg) by mouth in the morning and one tablet in the evening.
- Adults who cannot swallow tablets and children under 40 kg (89 lbs) should follow the instructions on how to prepare doxycycline for children and adults who cannot swallow pills, which tell individuals how to crush tablets and prepare the dose ([www.fda.gov/doxyprepare](http://www.fda.gov/doxyprepare)). These instructions are appropriate for tablet formulations, but not for capsules.
- Children weighing less than 14 kg (30 lbs) should receive priority for using doxycycline oral suspension, dosed by weight (see table below).
  - For the doxycycline powder for oral suspension (5 mg/mL) — Mix the doxycycline with water before you give the medication to the recipient, write the dose on the bottle, and mark the dose with a line on the syringe.
  - Tell the recipient to shake well the doxycycline oral suspension before each use.

Weight in Pounds (lbs)	Weight in kilograms (kg)	Dose in milliliters (mL) ( <i>based on 5mg/mL concentration</i> ) - Give one dose in the morning and one dose in the evening	Number of 60mL bottles provided to each patient to cover first 10 days of treatment
0-5 lbs	0-2 kg	1 mL	ONE (1) Bottle
6-10 lbs	3-4 kg	2 mL	
11-15 lbs	5-7 kg	3 mL	
16-20 lbs	8-9 kg	4 mL	TWO (2) Bottles
21-25 lbs	10-11 kg	5 mL	
26-30 lbs	12-14 kg	6 mL	

Recipients taking magnesium, aluminum antacids, sucralfate, Videx (didanosine), or products that contain calcium, iron, or zinc should take doxycycline at least 2 hours before, or 2 hours after, taking any of these other products.

<sup>1</sup> For more information about the benefits and risks of doxycycline, please see the FDA-approved package insert for doxycycline available at [www.dailymed.nlm.nih.gov](http://www.dailymed.nlm.nih.gov).

**Tell patients to STOP taking the medicine and get medical help immediately if they get any of the following possible serious side effects:**

- Serious allergic/hypersensitivity reactions sometimes fatal (anaphylactic and/or rashes)
- Severe stomach cramps with high fever or bloody diarrhea (antibiotic associated diarrhea and pseudomembranous colitis)
- Yellowing of the eyes or skin or dark-colored urine (liver failure)
- Pain when swallowing (esophageal ulcers). Tell recipients to drink a glass of water after taking doxycycline.
- Unusual bleeding or bruising
- Severe headaches, dizziness, or double vision

**But tell patients to keep taking the medicine if they have:**

- Mild nausea or vomiting
- Upset stomach, loose stools
- Vaginal yeast infection

**What are other possible serious side effects of doxycycline?**

- Doxycycline is safe to take during pregnancy, but if taken during the last half of pregnancy or when nursing, children may later have teeth problems (yellow-gray-brown permanent color changes and poor enamel formation); this may also occur in children under 8 years old who take doxycycline
- Slowed bone growth in children who take doxycycline
- Photosensitivity
- Birth control pills may not work as well. Recommend use of another form of birth control while taking doxycycline.

#### **Risk-Benefit Statement**

The significant known risks are those associated with the side effects described above. The expected benefits are prevention of disease, including death, associated with anthrax exposure. It is unknown how recipients will respond to the emergency instructions, how many recipients will receive the full, 60-day course of PEP, or what the impact of dispensing without an individual prescription will be. The benefit of mass dispensing to provide recipients with access to an initial supply of doxycycline is expected to outweigh the risks.

#### **Available Alternatives**

In this emergency situation, you will be informed of any alternative products that are available. The risks and benefits of those products are explained separately with those products.

#### **Reporting Adverse Event or Medication Errors**

You should report adverse events or medication errors to MedWatch at [www.fda.gov/medwatch](http://www.fda.gov/medwatch), by submitting a MedWatch Form 3500 (available at [http://www.fda.gov/medwatch/safety/FDA-3500\\_fillable.pdf](http://www.fda.gov/medwatch/safety/FDA-3500_fillable.pdf)) or by calling 1-800-FDA-1088.

**Give recipients the "Doxycycline EUA Fact Sheet for Recipients"**

#### **CONTACTS**

If you have any questions, please contact XXXXX (*placeholder for stakeholder's specific contact information*).